BC Innovations | May 15, 2019
Distillery Therapeutics

Cystine degradation boosts immunotherapies in melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Patient sample and mouse studies suggest promoting ferroptosis by degrading cystine could enhance the efficacy of anti-PD-1 immunotherapies in melanoma. In melanoma patients, high tumor levels of SLC7A11 and SLC3A2,...
BioCentury | Apr 28, 2014
Emerging Company Profile

Aeglea: Old enzymes, new tricks

Aeglea BioTherapeutics Holdings LLC is developing enzymes to starve tumors that depend on outside sources of specific amino acids. Aeglea's engineered human enzymes may offer lower immunogenicity and greater activity than natural versions further along...
Items per page:
1 - 2 of 2